In conclusion, HA121-28 demonstrated a promising antitumor activity in NSCLC with RET fusion; especially, CCDC6-RET patients showed a numerically higher response, and the cardiac risk associated with HA121-28 should be noted. The gene discussed is RET; the disease is non-small cell lung carcinoma.